Sorry, you need to enable JavaScript to visit this website.

NIMENRIX (Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine) Dosage And Administration

Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve. Click here to learn how we are responding.
Pfizer reconnaît les préoccupations du grand public concernant la situation liée à la COVID-19, qui continue d'évoluer. Cliquez ici pour savoir comment nous avons réagi.

Dosage And Administration

Dosing Considerations

NIMENRIX should be used in accordance with available official recommendations.

Recommended Dose and Dosage Adjustment

  1. Infants From 6 to 12 Weeks of Age

    Two-dose primary series
    The recommended immunization series consists of 2 doses (0.5 mL each) given 2 months apart. The doses should be given at 2 and 4 months of age, followed by a booster dose at 12 months of age. The first dose may be given as early as 6 weeks of age (see CLINICAL TRIALS – Immunogenicity: Immunogenicity in infants).

  2. Individuals From 12 Months of Age

    A single 0.5 mL dose should be administered.

NIMENRIX may be given as a booster dose to individuals who have previously received primary vaccination with NIMENRIX or other conjugated or plain polysaccharide meningococcal vaccines (see WARNINGS AND PRECAUTIONS – Protection Against Meningococcal Disease: Persistence of serum bactericidal antibody titres and CLINICAL TRIALS – Immunogenicity: Immunogenicity in toddlers aged 12-23 months).

A second dose of NIMENRIX may be considered appropriate for some individuals (see WARNINGS AND PRECAUTIONS – Protection Against Meningococcal Disease: Persistence of serum bactericidal antibody titres).

Administration

NIMENRIX is for intramuscular injection only.

The injection sites are the anterolateral aspect of the thigh in infants, or the anterolateral aspect of the thigh or deltoid muscle in individuals from 12 months of age (see WARNINGS AND PRECAUTIONS and DRUG INTERACTIONS).

For instructions on reconstitution of the vaccine before administration, see SPECIAL HANDLING INSTRUCTIONS.

The reconstituted vaccine is a clear colourless solution.

The reconstituted vaccine should be inspected visually for any foreign particulate matter and/or variation of physical aspect prior to administration. In the event of either being observed, discard the vaccine.

Any unused product or waste material should be disposed of in accordance with local requirements.

What's New

No Current Announcements.

Contact Pfizer Medical Information

Report an Adverse Event
1 866 723-7111